Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863861 | 0.97 | KCNH2 (0.42) | KCNH2MAP3K12CSF1RMAPK8MAPK9 | |
| SCHEMBL863455 | 0.96 | KCNH2 (0.45) | KCNH2IRAK4HRH3 | |
| SCHEMBL864693 | 0.92 | KCNH2 (0.46) | KCNH2HRH3 | |
| SCHEMBL863414 | 0.92 | HRH3 (0.38) | KCNH2MAP3K12CSF1RMAPK8MAPK9 | |
| SCHEMBL863725 | 0.88 | OTUD7B (0.37) | KCNH2HRH3 | |
| SCHEMBL863982 | 0.87 | HRH3 (0.40) | KCNH2HRH3 | |
| SCHEMBL7856633 | 0.87 | HRH3 (0.40) | KCNH2HRH3 | |
| SCHEMBL7858469 | 0.87 | HRH3 (0.40) | KCNH2HRH3 | |
| SCHEMBL7856993 | 0.87 | HRH3 (0.40) | KCNH2HRH3 | |
| SCHEMBL7856996 | 0.87 | HRH3 (0.40) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010144571-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077802-A1 | HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF | HRH3, HRH4, HRH2 | KCNH2 605/4885MAP3K12 1799/4885CSF1R 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.